Brachytherapy
Volume 9, Issue 1 , Pages 1-7 , January 2010

Rectal morbidity after permanent interstitial brachytherapy for prostate cancer—Impact of Day 1 vs. Day 30 computed tomography–based postimplant dosimetry

  • Michael Pinkawa

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, RWTH Aachen University, Pauwelsstrasse 30, 52057 Aachen, Germany. Tel.: +49-241-80-35314; fax: +49-241-80-82543.
    • ,
  • Marc D. Piroth

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • ,
  • Richard Holy

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • ,
  • Jens Klotz

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • ,
  • Sandra Nussen

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany
    • ,
  • Holger Borchers

      Affiliations

    • Department of Urology, RWTH Aachen University, Aachen, Germany
    • ,
  • Axel Heidenreich

      Affiliations

    • Department of Urology, RWTH Aachen University, Aachen, Germany
    • ,
  • Michael J. Eble

      Affiliations

    • Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany

Received 16 March 2009 ,Revised 24 April 2009 ,Accepted 28 April 2009.

References 

  1. Theodorescu D, Gillenwater JY, Koutrouvelis PG, et al. Prostatourethral-rectal fistula after prostate brachytherapy: Incidence and risk factors. Cancer. 2000;89:2085–2091
  2. Tran A, Wallner K, Merrick GS, et al. Rectal fistulas following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;63:150–154
  3. Snyder KM, Stock RG, Hong SM, et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;50:335–341
  4. Waterman FM, Dicker AP. Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:342–353
  5. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–799
  6. Salembier C, Lavagnini P, Nickers P, et al. Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol. 2007;83:3–10
  7. Zelefsky MJ, Yamada Y, Cohen G, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:65–70
  8. Crook JM, Potters L, Stock RG, et al. Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy. 2005;4:186–194
  9. Pinkawa M, Asadpour B, Piroth MD, et al. Rectal dosimetry following brachytherapy with stranded seeds—Comparison of transrectal ultrasound intra-operative planning (day 0) and computed tomography-postplanning (day 1 vs. day 30) with special focus on sources placed close to the rectal wall. Radiother Oncol. 2009;91:207–212
  10. Pinkawa M, Gagel B, Asadpour B, et al. Seed displacements after permanent brachytherapy for prostate cancer in dependence on the prostate level. Strahlenther Onkol. 2008;184:520–525
  11. Taussky D, Yeung I, Williams T, et al. Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:358–363
  12. Reed DR, Wallner K, Ford E, et al. Effect of post-implant edema on prostate brachytherapy treatment margins. Int J Radiat Oncol Biol Phys. 2005;63:1469–1473
  13. Pinkawa M, Asadpour B, Gagel B, et al. Evaluation of source displacement and dose-volume changes after permanent prostate brachytherapy with stranded seeds. Radiother Oncol. 2007;84:190–196
  14. Pinkawa M, Siluschek J, Gagel B, et al. Influence of the initial rectal distension on posterior margins in primary and postoperative radiotherapy for prostate cancer. Radiother Oncol. 2006;81:284–290
  15. de Crevoisier R, Tucker SL, Dong L, et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:965–973
  16. Volz-Sidiropoulou E, Pinkawa M, Fischedick K, et al. Factor analysis of the Expanded Prostate Cancer Index Composite (EPIC) in a patient group after primary (external beam radiotherapy and permanent iodine-125 brachytherapy) and postoperative radiotherapy for prostate cancer. Curr Urol. 2008;2:122–129
  17. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905
  18. Ososba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–144
  19. Dogan N, Mohideen N, Glasgow GP, et al. Effect of prostatic edema on CT-based postimplant dosimetry. Int J Radiat Oncol Biol Phys. 2002;53:483–489
  20. Hoffelt SC, Wallner K, Merrick G, et al. Epididymitis after prostate brachytherapy. Urology. 2004;63:293–296
  21. Narayana V, Roberson PL, Pu AT, et al. Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants. Int J Radiat Oncol Biol Phys. 1997;37:1181–1185
  22. Villeirs GM, Van Vaerenbergh K, Vakaet L, et al. Interobserver delineation variation using CT versus CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol. 2005;181:424–430
  23. Pinkawa M, Gagel B, Holy R, et al. Reliability of CT-based postimplant values in interstitial permanent brachytherapy. Radiother Oncol. 2004;71:S122
  24. Pinkawa M, Gagel B, Piroth MD, et al. Changes of dose delivery distribution within the first month after permanent interstitial brachytherapy for prostate cancer. Strahlenther Onkol. 2006;182:525–530
  25. Zelefsky MJ, Nedelka MA, Arican ZL, et al. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: Reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy. Brachytherapy. 2008;7:1–6
  26. Merrick GS, Butler WM, Dorsey AT, et al. The effect of constipation on rectal dosimetry following prostate brachytherapy. Med Dosim. 2000;25:237–241
  27. Fantin AC, Binek J, Jabar FM, et al. Argon beam coagulation for treatment of symptomatic radiation-induced proctitis. Gastrointest Endosc. 1999;49:515–518
  28. Ehrenpreis ED, Jani A, Levitsky J, et al. A prospective, randomized, double-blind, placebo-controlled trial of retinol-palmitate (vitamin A) for symptomatic chronic radiation proctopathy. Dis Colon Rectum. 2005;48:1–8
  29. Pinkawa M, Fischedick K, Asadpour B, et al. Low-grade toxicity after conformal radiation therapy for prostate cancer—Impact of bladder volume. Int J Radiat Oncol Biol Phys. 2006;64:835–841
  30. van der Kogel AJ. Radiation response and tolerance of normal tissues. In:  Steel GG editors. Basic clinical radiobiology. London: Arnold; 2002;p. 30–41
  31. Yeoh EK, Holloway RH, Fraser RJ, et al. Anorectal function after three- versus two-dimensional radiation therapy for carcinoma of the prostata. Int J Radiat Oncol Biol Phys. 2009;73:46–52
  32. Mueller A, Wallner K, Merrick G, et al. Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding. Int J Radiat Oncol Biol Phys. 2004;59:1047–1052
  33. Michalski JM, Ciezki J, Kaplan I, et al. Early complications following contemporary brachytherapy for prostate cancer in a multi-institutional study at high volume health-centers in the US. Int J Radiat Oncol Biol Phys. 2006;66:S323–S324
  34. Prete JJ, Prestidge BR, Bice WS, et al. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys. 1997;40:519–527
  35. Pinkawa M, Maurer U, Mulhern A, et al. Inverse automated treatment planning with and without individual optimization in interstitial permanent prostate brachytherapy with high- and low-activity 125I. Strahlenther Onkol. 2003;179:417–422
  36. Narayana V, Troyer S, Evans V, et al. Randomized trial of high- and low-source strength 125I prostate seed implants. Int J Radiat Oncol Biol Phys. 2005;6:44–51

PII: S1538-4721(09)00266-9

doi: 10.1016/j.brachy.2009.04.003

Brachytherapy
Volume 9, Issue 1 , Pages 1-7 , January 2010

Article Tools

* Image Usage & Resolution